Log in to search using one of your social media accounts:

 

Hologic to retain CEO MacMillan | Personnel Moves – November 3, 2017
Hologic (NSDQ:HOLX) said this week its current prez and CEO Stephen MacMillan will stay on with the company, resolving rumors that he may depart it to take up the corner office at Zimmer Biomet (NYSE:ZBH). In an SEC filing, the Marlborough, Mass.-based company’s board said it approved a special “performance-based retention equity grant” to MacMillan after he had begun to receive interest from other medical device firms. “Mr. MacMillan has led a dramatic turnaround of Hologic since joining in December 2013. The company’s performance has increased significantly under his...
Source: Mass Device - November 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News ConMed Corp. Hologic Invacare kentimaging Meritech Capital Partners Pulmatrix Inc. Sanofi-Aventis Smith & Nephew Tissue Regenix zimmerbiomet Source Type: news

Wright Medical shares tumble on Q3 sales miss, growing losses
Shares in Wright Medical (NSDQ:WMGI) fell today after the medical device maker missed sales expectations on Wall Street with its 3rd quarter earnings results. The Netherlands-based company posted losses of $131.9 million, or $1.26 per share, on sales of $170.5 million for the 3 months ended September 30, seeing losses grow 19.7% while sales grew a smaller 8.4% compared with the same period last year. Adjusted to exclude 1-time items, losses per share were 16¢, just ahead of the 17¢ consensus on Wall Street, where analysts expected to see revenue of $173.6 million. “Our U.S. upper extremities business h...
Source: Mass Device - November 2, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup wrightmedical Source Type: news

MiMedx Agrees To Lawsuit Settlement With Halo Wound Solutions
MARIETTA, Ga., Nov. 1, 2017 -- (Healthcare Sales & Marketing Network) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts a... Devices, Regenerative Medicine, Wound Care, Litigation MiMedx, Halo Wound Solutions (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 1, 2017 Category: Pharmaceuticals Source Type: news

Arthrosurface acquires allograft tech from Wasas
Arthrosurface said today that it paid an unspecified amount to acquire an acellular dermal stabilization device technology from Wasas LLC. Derived from human tissue, acellular dermis is made using a process that removes cells but retains portions of the extracellular matrix to create dermal allografts. The deal includes the patent rights for the technology, which Franklin, Mass.-based Arthrosurface plans to develop and market “a platform of novel methods to be used to correct orthopedic challenges” for several indications. Wasas is based in Ft. Lauderdale. “The availability of this allograf...
Source: Mass Device - October 30, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Orthopedics Wall Street Beat Arthrosurface wasas Source Type: news

NASS 2017 Roundup: Zimmer Biomet launches Vitality+, Vital spinal fixation systems
Zimmer Biomet (NYSE:ZBH) today announced the launch of its Vitality+ and Vital spine fixation systems in the US following recent 510(k) clearance for pedicle preparation and screw insertion under power. The Vitality+ spinal fixation system is composed of a Vitality+ Power designed for controlled pedicle preparation and pedicle screw insertion, Vitality+ PSO designed for optimal pedicle subtraction osteotomy and vertebral column resection and Vitality+ Hooks for additional fixation options, the Warsaw, Ind.-based company said. The recent clearance allows the inclusion of the market’s first flexible drill and blun...
Source: Mass Device - October 25, 2017 Category: Medical Devices Authors: Fink Densford Tags: Spinal depuysynthes gssolutions johnsonandjohnson LifeNet Health Misonix Mizuho OSI Nuvasive RTI Surgical Xtant Medical zimmerbiomet Source Type: news

LifeNet Health Provides Uncompromised Fusion Solution with Launch of PliaFX(R) Strip
Presentations at NASS Annual Meeting (Booth 1113) will highlight the technology behind PliaFX Strip ORLANDO, Fla., Oct. 25, 2017 -- (Healthcare Sales & Marketing Network) -- LifeNet Health has introduced its latest allograft bone-healing solution, the ... Devices, Orthopaedic, Product Launch LifeNet Health, PliaFX, allograft (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 25, 2017 Category: Pharmaceuticals Source Type: news

TGF-{beta} receptor I/II trafficking and signaling at primary cilia are inhibited by ceramide to attenuate cell migration and tumor metastasis
Signaling by the transforming growth factor–β (TGF-β) receptors I and II (TβRI/II) and the primary cilia-localized sonic hedgehog (Shh) pathway promote cell migration and, consequently, tumor metastasis. In contrast, the sphingolipid ceramide inhibits cell proliferation and tumor metastasis. We investigated whether ceramide metabolism inhibited TβRI/II trafficking to primary cilia to attenuate cross-talk between TβRI/II and the Shh pathway. We found that ceramide synthase 4 (CerS4)–generated ceramide stabilized the association between TβRI and the inhibitory factor Smad7, which lim...
Source: Signal Transduction Knowledge Environment - October 24, 2017 Category: Science Authors: Gencer, S., Oleinik, N., Kim, J., Panneer Selvam, S., De Palma, R., Dany, M., Nganga, R., Thomas, R. J., Senkal, C. E., Howe, P. H., Ogretmen, B. Tags: STKE Research Articles Source Type: news

R3 Stem Cell Now Offering Amniotic Membrane Allograft for Effective...
Regenerative medicine company R3 Stem Cell is now offering amniotic membrane allograft for eye care treatment. The membranes are safe, effective, FDA regulated and excellent for all types of...(PRWeb October 23, 2017)Read the full story at http://www.prweb.com/releases/amnioticmembraneallograft/r3-stem-cell/prweb14831115.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 23, 2017 Category: Pharmaceuticals Source Type: news

NuVasive Receives Expanded FDA 510(k) Clearance For TLX Interbody System Used In TLIF Procedures
New clearance for TLX™ system includes indications for use with allogeneic bone graft and in additional levels of the spine; Technology to be showcased at NASS 2017 SAN DIEGO, Oct. 16, 2017 -- (Healthcare Sales & Marketing Network) -- NuVasive, Inc. (N... Devices, Neurosurgery, Orthopaedic, FDA NuVasive, TLX interbody, TLIF, spine surgery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 16, 2017 Category: Pharmaceuticals Source Type: news

FDA expands indication for NuVasive ’ s TLX spine implant
NuVasive Inc. (NSDQ:NUVA) said today the it won expanded 510(k) clearance from the FDA for its TLX implant used in spinal fusion surgery. San Diego-based NuVasive said the new clearance covers an new, expandable 20° cage and new indications for use covering allogeneic bone grafts and more spine levels. “With the additional clearance for our latest TLX system, we now provide the leading tools for [transforaminal lumbar interbody fusion] procedures with our MAS TLIF solution, validating our commitment to improving spine solutions,” strategy, technology & corporate development EVP Matt Link said in pr...
Source: Mass Device - October 16, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Orthopedics Regulatory/Compliance Spinal Nuvasive Source Type: news

Hamstring autograft with preserved insertions linked to improved outcomes compared to free autograft for ACL patients
A study published online in the journal Arthroscopy compares differences in short-term outcomes for patients who undergo anterior cruciate ligament (ACL) reconstruction using a graft with preserved insertions and those treated with a free hamstring graft.  (Source: Orthogate - Latest News)
Source: Orthogate - Latest News - October 15, 2017 Category: Orthopaedics Tags: Featured Editors Choice News Source Type: news

Dr. Gloria Matthews Joins MiMedx As Its Senior Vice President Of Research And Development
MIMEDX REAFFIRMS LATEST THIRD QUARTER OF 2017 REVENUE EXPECTATIONS MARIETTA, Ga., Oct. 3, 2017 -- (Healthcare Sales & Marketing Network) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative a... Devices, Regenerative Medicine, Personnel MiMedx Group, PURION, placental tissue allograft (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 3, 2017 Category: Pharmaceuticals Source Type: news

OSTEOPOROSIS: How weak bones could leave you inches shorter
WHEN Christine Howis broke her arm at the age of 51, she thought it was no more than an accident – even though she eventually needed a bone graft when it failed to heal properly. (Source: Daily Express - Health)
Source: Daily Express - Health - September 26, 2017 Category: Consumer Health News Source Type: news

Treatment of Large Bone Defect from Root Fracture
In this case, a large bone defect, as a consequence of fractured roots of the first molar, was augmented by Bond Apatite bone graft cement. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - September 25, 2017 Category: Dentistry Authors: osseonews Tags: Clinical Cases Regenerative Source Type: news

Tiny diamonds could become best friends to youths with cleft palates
This study showed that our method has a contained, targeted and sustained effect, so we’re very excited about it,” Hong said.Previous experiments showed nanodiamonds to be safe within the body and to be excreted normally. Similarly, earlier work demonstrated that enzymes break down hydrogel.The researchers plan to continue laboratory studies and hope to bring their treatment to clinical trials. Their approach has implications for treating other craniofacial conditions and sleep apnea, as well as healing wounds and bone injuries.Other authors of the study were Dong-Keun Lee, Lawrence Lin, Hsin Chuan Pan, Deborah...
Source: UCLA Newsroom: Health Sciences - September 22, 2017 Category: Universities & Medical Training Source Type: news

Will Small Companies See a Bigger Impact from Hurricanes?
Cardiovascular Systems Inc. said Monday that its procedure volumes took a hit in the Houston, TX, and Florida markets, which account for more than 15% of the company’s revenue, in the aftermath of Hurricanes Harvey and Irma. To add insult to injury, the company reported that September is normally its strongest month for procedures within the quarter, which means the fiscal first quarter revenues are more heavily weighted in September.  The company is based in St. Paul, MN, but has a facility in Pearland, TX, near Houston. "As recovery progresses, we will closely monitor conditions and the anticipated i...
Source: MDDI - September 19, 2017 Category: Medical Devices Authors: Amanda Pedersen Tags: MD & M Minneapolis Medical Device Business Source Type: news

MiMedx loses appeal in placental allograft tissue patent spat
A Federal Circuit Court this week affirmed a Patent Trial and Appeal Board ruling which found a MiMedx (NSDQ:MDXG) tissue graft patent invalid in a spat between the company and the Musculoskeletal Transplant Foundation. The ruling came from a 3-judge panel, delivered in a 1-line order without an opinion, affirming the PTAB’s decision from last month which found the patent as invalid as obvious, according to court documents. The spat is related to a dehydrated human amnion/chorion membrane placental tissue allograft patent, with Marietta, Ga.-based MiMedx claiming that the MTF infringed upon it with their own gra...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Legal News Patent Infringement MiMedx Group Inc. Source Type: news

MiMedx Notified By FDA That It Can Proceed With Phase 3 Investigational New Drug Clinical Trial For Achilles Tendonitis
MARIETTA, Ga., Sept. 7, 2017 -- (Healthcare Sales & Marketing Network) -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts ... Biopharmaceuticals, Regenerative Medicine, Orthopaedic, FDA MiMedx Group, AmnioFix, achilles tendonitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 7, 2017 Category: Pharmaceuticals Source Type: news

Never say never again: a bone graft infection due to a hornet sting, thirty-nine years after cranioplasty - Maugeri R, Giammalva RG, Graziano F, Basile L, Gul ì C, Giugno A, Iacopino DG.
BACKGROUND: Cranioplasty (CP) is a widespread surgical procedure aimed to restore skull integrity and physiological cerebral hemodynamics, to improve neurological functions and to protect the underlying brain after a life-saving decompressive craniectomy (... (Source: SafetyLit)
Source: SafetyLit - September 7, 2017 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

MassDevice.com +5 | The top 5 medtech stories for September 5, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. How medical device risk management is connected with design controls Medical device design controls play an important role when it comes to risk management, but the relationship isn’t always immediately clear. Intended us...
Source: Mass Device - September 5, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Medtronic launches long-term PLF, TLIF Infuse bone protein study
Medtronic (NYSE:MDT) said today it launched a long-term clinical study of its Infuse bone graft for use during posterolateral fusion and transforaminal lumbar interbody fusion spine procedures. The 1st patient in the study was enrolled at Indiana’s Fort Wayne Orthopedics and underwent a procedure led by Dr. Kevin Rahn and Dr. Robert Shugart, Fridley, Minn.-based Medtronic said. “Failed back surgery is a real concern with long-term implications, and successful outcomes in PLF and TLIF procedures require solid fusion. We believe there is significant data on the safety and efficacy profile of Infuse in approv...
Source: Mass Device - September 5, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Spinal Medtronic Source Type: news

Bone Binders for bone augmentation?
Do you know of any bone binders used in oral bone augmentation procedures that would not interfere with osteogenesis, resorb parallel with bone graft material and be biologically inert? (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - August 30, 2017 Category: Dentistry Authors: osseonews Tags: Clinical Questions Regenerative Source Type: news

Metro Atlanta's MiMedx to spin out subsidiary to focus on biopharma
Marietta-based MiMedx Group, Inc. (NASDAQ: MDXG) has signed an agreement to divest the company's subsidiary, Stability Biologics LLC, back to its original stockholders. MiMedx's said its transition into a biopharmaceutical company was an impetus for this divestiture initiative. MiMedx Group is developing and marketing regenerative and therapeutic biologics with human placental tissue allografts and patent-protected processes for multiple sectors of health care. In January of 2016, the company acquired… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - August 21, 2017 Category: American Health Authors: Eric Mandel Source Type: news

MiMedx divests Stable Biologics subsidiary in transition to focus on biopharma
MiMedx (NSDQ:MDXG) said today it inked a definitive agreement with the former shareholders of Stability Inc. to divest itself of Stability Biologics, which it acquired last January. The Marietta, Ga.-based company said the divestiture is part of its plan to transition back into a biopharmaceutical-focused company. “The transaction is expected to be completed in the 3rd quarter of 2017, and the consideration will include a promissory note issued by Stability Biologics in the principal amount of $3.5 million in favor of MiMedx and a waiver by the former stockholders of Stability, Inc. ...
Source: Mass Device - August 18, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Mergers & Acquisitions Regenerative Medicine MiMedx Group Inc. Stability Biologics Source Type: news

Camber spine wins FDA nod for Spira interbody fusion device
Camber Spine Technologies said today it won FDA 510(k) clearance from the FDA for its Spira open matrix anterior lumbar interbody fusion device. The Wayne, Penn.-based company said the Spira device consists of spiral support arches designed to increase fusion rates and stabilization. The company said the spiral support arches also decrease subsidence by load sharing over the entire endplate while also maximizing bone graft capacity. “Camber Spine is very excited to be launching our first in a series of spinal implants using 3D printed – additive manufacturing. This specialized manufacturing technology allows us...
Source: Mass Device - August 16, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Regulatory/Compliance Spinal camberspine Source Type: news

Prolonged Allograft Survival in Chronic Immunosuppression Prolonged Allograft Survival in Chronic Immunosuppression
This review explores the potential for the indefinite survival of a skin allograft among transplant patients on chronic immunosuppression.Wounds (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 15, 2017 Category: Intensive Care Tags: General Surgery Journal Article Source Type: news

Pain and itch outcome trajectories differ among European American and African American survivors of major thermal burn injury
Over half of individuals experiencing major thermal burn injury (MThBI) receive an autologous skin graft (autograft), in which skin is removed from a healthy " donor " site and transplanted to the burn site. Persistent pain/itch at the graft site are major causes of suffering and disability in MThBI survivors. African Americans have a higher risk of MThBI, and in other clinical settings African Americans experience a greater burden of pain and itch relative to European Americans. However, to our knowledge, ethnic differences in skin graft site pain/itch outcomes after MThBI have not been assessed. We evaluated sk...
Source: Current Awareness Service for Health (CASH) - August 14, 2017 Category: Consumer Health News Source Type: news

7 medtech stories we missed this week: August 11, 2017
[Image from unsplash.com]From Xtant Medical’s 510(k) extension to Varian Medical’s distribution deal, here are seven medtech stories we missed this week but thought were still worth a mention. 1. FDA extends Xtant Medical’s 510(k) for Calix C spinal implant Xtant Medical announced in an Aug. 9 press release that the FDA has cleared its product line extensions for the Calix-C cervical inter body cages. The clearance allows for two larger footprints to be added for use with allograft. The Calix-C Cervical Interbody Spacer is designed for spinal fusion procedures at level one in patients who are skeletally m...
Source: Mass Device - August 11, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Cardiovascular Clinical Trials Food & Drug Administration (FDA) Oncology Regulatory/Compliance Spinal Surgical Apifix Cardiac Science Hip Innovation Life Spine Inc. MedTech Pentax Medical Varian Medical Systems Xtant M Source Type: news

Immediate implant placement into posterior sockets with or without buccal bone dehiscence defects: A retrospective cohort study
ConclusionsWithin the limitations of this study, flapless implant placement into compromised sockets in combination with DBBM grafting may be a viable technique to reconstitute the defected buccal bone plates due to space maintenance and primary socket closure provided by healing abutments and bone grafts.Clinical significanceImmediate implants and DBBM grafting without using membranes may be indicated for sockets with buccal bone defects. (Source: Dental Technology Blog)
Source: Dental Technology Blog - August 4, 2017 Category: Dentistry Source Type: news

Wright Medical shares rise on Q2 beat
Shares in Wright Medical (NSDQ:WMGI) rose yesterday after the medical device maker beat expectations on Wall Street with its 2nd quarter earnings results. The Amsterdam-based company posted losses of $41.2 million, or 39¢ per share, on sales of $179.7 million for the 3 months ended June 25, seeing losses shrink 82.1% while sales grew 5.3% compared with the same period during the prior year. Adjusted to exclude 1-time items, losses per share were 7¢, just ahead of the 9¢ loss per share consensus on The Street, where analysts were looking for sales of $178.2 million for the quarter. “All of our most...
Source: Mass Device - August 4, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News MassDevice Earnings Roundup Wall Street Beat wrightmedical Source Type: news

Exposure of threads after bone graft?
I recently uncovered an implant after about 3 months. About 1-2mm of the buccal threads were exposed. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - July 31, 2017 Category: Dentistry Authors: osseonews Tags: Clinical Questions Regenerative Source Type: news

Biopsies to Identify Patients at Risk for Allograft Loss Biopsies to Identify Patients at Risk for Allograft Loss
Serial allograft biopsies may help determine which patients with de novo donor-specific antibodies are most likely to experience allograft loss.American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 19, 2017 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

Radiolucent lesion and immature bone: Proceed with caution?
Tooth #19 had failed RCT with infection and fistula and large radiolucent lesion.  It was extracted and a bone graft done and implant placed 5 months later. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - July 13, 2017 Category: Dentistry Authors: osseonews Tags: Clinical Cases Surgical Source Type: news

MassDevice.com +5 | The top 5 medtech stories for July 3, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. BD extends Bard note exchange offering again Becton Dickinson said today is once again extending its exchange offering for up to $1.1 billion in outstanding C. R. Bard notes from July 3 to August 1. The company is offering exch...
Source: Mass Device - July 3, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Medtronic nearing resolution on Infuse suits
Medtronic (NYSE:MDT) is closing in on a resolution to the long-running legal battles over its Infuse bone-growth protein designed for back surgeries, according to an SEC filing posted last week. The Fridley, Minn.-based company said that it is approaching agreements to settle approximately 6,000 cases against it which asserted personal injury claims due to the bone graft product in an SEC filing. “As of June 1, 2017, the company has reached agreements to settle substantially all of these claims, resolving this litigation,” Medtronic wrote in an SEC filing. While Medtronic did not release exact financial de...
Source: Mass Device - July 3, 2017 Category: Medical Devices Authors: Fink Densford Tags: Legal News Regenerative Medicine Spinal Medtronic Source Type: news

Socket Grafting and Ridge Preservation using Bond Apatite
The socket and the ridge were preserved by augmenting the area with Bond apatite bone graft cement. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - June 30, 2017 Category: Dentistry Authors: osseonews Tags: Clinical Cases Regenerative Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 29, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. DeviceTalks: 3M’s Cindy Kent on leadership, growth and inclusion in medtech Cindy Kent is no stranger to medtech – she’s spent 20 years in healthcare, moving up the ranks and finding her way to president &...
Source: Mass Device - June 29, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

Spineology wins FDA nod for Rampart One lumbar interbody fusion system
Spinal tech developer Spineology said this week it won FDA clearance for its Rampart One anterior lumbar interbody fusion system. The St. Paul, Minn.-based company said the Rampart One is designed to minimize exposure and vascular retraction requirements associated with traditional anterior spine fusion procedure, and includes both standard and oblique interbody device footprints with integrated fixation screws. “Variable angle instrumentation and integrated guides are colinear with the access, providing the surgeon the ability to keep the incision to a minimum,” Dr. Jeremy Shore said in a prepared stateme...
Source: Mass Device - June 29, 2017 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Regulatory/Compliance Spinal Spineology Source Type: news

Bonesupport closes $57m IPO
BoneSupport said last week it closed its initial public offering, raising a total of approximately $57.1 million (SEK 500 million), not including an over-allotment option. The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it floated approximately 17.2 million new shares at $3.40 per share (SEK 29) in the round, raising approximately $57.1 million before issue costs and $54 million (SEK 461 million) after issue costs. Read the whole story at our sister site, Drug Delivery Business The post Bonesupport closes $57m IPO appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 29, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Initial Public Offering (IPO) Orthopedics Bonesupport Source Type: news

7 medtech stories we missed this week: June 23, 2017
[Image from unsplash.com]From Guardant suing Foundation Medicine to Interson receiving 510(k) clearance for ultrasound probes, here are 7 medtech stories we missed this week but thought were still worth mentioning. 1. Guardant levels false advertising suit against Foundation Medicine Guardant Health announced in a June 22 press release that it has filed a lawsuit against Foundation Medicine for false advertising and unfair competition. Guardant Health is claiming that Foundation Medicine’s advertising causes harm to Guardant Health and its patients because it misleads oncologists about the sensitivity and accuracy of...
Source: Mass Device - June 23, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: 510(k) Business/Financial News Clinical Trials Food & Drug Administration (FDA) Implants Neurological Regulatory/Compliance Ultrasound EndoStim Foundation Medicine Inc. Guardant Health Interson Lee's Pharmaceutical Meditech Med Source Type: news

Swiss Kuros Biosciences wins CE Mark for NeuroSeal dural sealant
Swiss tissue repair and regenerative med focused Kuros Biosciences said today it won CE Mark approval in the European for its Neuroseal novel dural sealant. The Neuroseal sealant is designed as an adjunct to suturing and is used to seal the dura after cranial surgery and reduce the risk of cerebrospinal fluid leakage, the company said. Kuros added that the sealant was designed to be easy to prepare, use and handle to reduce adverse effect risks. Kuros Biosciences said that the approval is the 2nd for the company following the approval of its MagnetOs Granules, a novel synthetic bone graft substitute designed to regenerate ...
Source: Mass Device - June 22, 2017 Category: Medical Devices Authors: Fink Densford Tags: Regulatory/Compliance Surgical kurosbiosciences Source Type: news

BoneSupport readies $62m IPO
BoneSupport said this week that it’s planning to float an initial public offering that would fetch roughly $62 million at the midpoint, not including an over-allotment option. The Swedish company, which is developing the Cerament G injectable antibiotic-eluting bone graft substitute, said it plans to offer more than 18.5 million shares at $3.13 to $3.59 apiece (SEK 27 to SEK 31), for total proceeds of $57.9 million to $66.4 million (SEK 500 million to SEK 574 million). Get the full story at our sister site, Drug Delivery Business News.  The post BoneSupport readies $62m IPO appeared first on MassDevice...
Source: Mass Device - June 14, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Funding Roundup Initial Public Offering (IPO) Orthopedics Wall Street Beat Bonesupport Source Type: news

Silver Spring tissue regeneration company raises $12 million
Silver Spring regenerative medicine company Aziyo Biologics Inc. raised $12 million in a recent funding round, a Securities and Exchange Commission filing shows. HighCape Partners, a New York equity fund and majority owner of Aziyo, led the funding round for the local company, which creates customized human tissue products for use in orthopedic, spinal, sports medicine and dermal surgeries. Several of its products are allografts — or tissue grafts from d onors — for bone repair, ligament replacement… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 14, 2017 Category: Pharmaceuticals Authors: Tina Reed Source Type: news

How to rehabilitate the maxillary arch?
 I am considering as my primary treatment plan doing bilateral sinus lifts with bone grafts and installing 3 implants on each side or All on 4. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - June 12, 2017 Category: Dentistry Authors: osseonews Tags: Clinical Cases Surgical Source Type: news

Bioventus expands market access for surgical products with new contract
When Durham-based Bioventus acquired OSTEOAMP – a bone fusion solution – from Advanced Biologics back in 2014, the product was already on contract with Premier, Inc. (Nasdaq: PINC), which has an alliance of 3,750 hospitals and upward of 130,000 other organizations across the U.S. Three years later, Bioventus has secured a new contract with Premier for its full, nine-product surgical portfolio, which includes bone grafts and marrow extraction devices, among other products. The new contract “improves… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 8, 2017 Category: American Health Authors: Jennifer Henderson Source Type: news

Infection of Grafted Site: recommendations?
This patient had peri-implantitis. I grafted the area with Bio-Oss, allograft and autogenous mixed with PRF serum and held in place with titanium-reinforced membrane. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - June 7, 2017 Category: Dentistry Authors: osseonews Tags: Clinical Cases Regenerative Source Type: news

Mallinckrodt launches pivotal trial for StrataGraft regenerative skin graft
Mallinckrodt (NYSE:MNK) said today that it enrolled the 1st patient in the pivotal Phase III trial of its StrataGraft skin tissue graft. The study is slated to include patients with 3% to 49% total body surface area of severe thermal burns. Researchers intend to evaluate outcomes including the area of StrataGraft treatment site that requires a subsequent autograft compared to the control site and the proportion of participants that achieve durable wound closure of the treatment site without autograft placement. Get the full story at our sister site, Drug Delivery Business News. The post Mallinckrodt launches pivo...
Source: Mass Device - June 7, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Regenerative Medicine Wall Street Beat Mallinckrodt Source Type: news

NovaBone launches bioactive bone graft substitutes
NovaBone Products added NovaBone IRM and IRM MacroPOR to its portfolio of biologically active bone graft substitutes today. The Jacksonville, Fla.-based company touted its devices as the industry’s most advanced bioactive synthetic bone graft substitutes available for orthopedic applications. The 2 new formulations are highly irrigation resistant and promote osteogenesis and osteoblastic activity, according to NovaBone. Get the full story at our sister site, Drug Delivery Business News. The post NovaBone launches bioactive bone graft substitutes appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 25, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Orthopedics Regenerative Medicine Surgical Wall Street Beat NovaBone Source Type: news

Custom 3D-Printed Resorbable Bone Grafts for Ridge Augmentation
The image is then printed by a 3D printer, producing a resorbable bone graft that fits your patient precisely. (Source: Dental Implants Discussed by Experts)
Source: Dental Implants Discussed by Experts - May 25, 2017 Category: Dentistry Authors: osseonews Tags: Clinical Cases Regenerative Source Type: news

MassDevice.com +5 | The top 5 medtech stories for May 22, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters.   5. BoneSupport launches trial of antibiotic-eluting bone graft BoneSupport said today that the 1st patient has been enrolled in the pivotal investigational device exemption trial for its injectable antibiotic-eluting bone graft su...
Source: Mass Device - May 22, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news